Life Science News

The New Brunswick Health Research Foundation partners with Cloud DX to fund Calibration and Validation research of its patented Pulsewave 2.0, a Non-Invasive Vital Sign Monitoring DeviceNews in SummaryNBHRF is providing $131,902 to the New Brunswick research team for ongoing research of the clinical evaluation of the wrist-worn vital sign monitoring device, Pulsewave 2.0Cloud DX commits to R&D investment for ...

The New Brunswick Health Research Foundation (NBHRF) partners with Cloud DX to fund Calibration and Validation research of its patented Pulsewave 2.0, a Non-Invasive Vital Sign Monitoring Device

News in Summary

  • NBHRF is providing $131,902 to the New Brunswick research team for ongoing research of the clinical evaluation of the wrist-worn vital sign monitoring device, Pulsewave 2.0
  • Cloud DX commits to R&D investment for clinical calibration and subsequent validation of a wrist-worn non-invasive health monitoring device to be conducted at the Horizon Health Network, Saint John Regional Hospital (SJRH)
  • The NBHRF supports, facilitates, and promotes innovative health research in New Brunswick, Canada
  • Research findings and data will be used for Health Canada licensing and FDA clearance of Cloud DX's next-generation Pulsewave 2.0, on its path to market as the only wrist cuff to accurately measure pulse rate, blood pressure, and respiratory rate in both home and clinical settings

Cloud DX (TSXV:CDX)(OTCQB:CDXFF), Cloud DX announces new partner funding from the New Brunswick Health Research Foundation (NBHRF). This funding will support ongoing clinical calibration and subsequent validation trials with the Cloud DX Pulsewave 2.0 wrist-worn vital sign monitoring device

The NBHRF Strategic Initiative Grant will be matched two to one by Cloud DX over three years to support the ongoing research and development led by Dr. Brunt and Dr. Teskey and their teams at Cardiovascular Research New Brunswick (CVR NB), Dalhousie Medicine New Brunswick (DMNB), University of New Brunswick (UNB) and the IMPART investigator team. The research will be conducted with the Department of Cardiology at the New Brunswick Heart Center at the Saint John Regional Hospital (SJRH), part of the Horizon Health Network.

Lead researcher & Translational Scientist, Dr. Keith Brunt states: "We are pleased to provide ongoing best-in-class R&D support to the development of medical technology innovations. We are committed to ensuring informed-decision making clinically is built upon strong evidence, validated intellectual property that is peer-reviewed and aligned with regulatory expectations for medical devices. Our prior clinical research with an earlier version of the device, was published in the Journal of Medical Internet Research, and key to the initial development of proprietary algorithms for the Pulsewave 2.0 device."

Dr. Robert Teskey, an Interventional Cardiologist with the Horizon Health Network, New Brunswick Heart Centre added that "Clinically accurate vital sign monitoring at home is essential for our cardiac patients. This funding will support the ongoing clinical calibration and validation of the Cloud DX, Inc. Pulsewave 2.0, the non-invasive vital sign monitoring device."

Cloud DX is in the process of clinically calibrating the PAD-2A device in preparation for subsequent clinical validation with the ISO 2020_AMD 1 universal protocol in order to submit the validation data to Health Canada and the FDA for licensing and clearance, respectively. This will satisfy the federal regulatory requirements in order to serve the market needs in Canada and the United States.

As with its other devices, Cloud DX will include the Pulsewave 2.0 device in its Connected Health™ virtual care and remote patient monitoring solution upon clinical validation by the research team and subsequent licensing and clearance by the federal regulatory agencies.

"Cloud DX deeply appreciates this financial support for our research partners Horizon Health, University of New Brunswick, and Dalhousie Medicine NB", stated Robert Kaul, Cloud DX CEO and Founder. "By funding the clinical studies required to achieve Health Canada licensing and FDA clearance, organizations like the NBHRF play an integral role in helping Canadian companies produce medical devices at home here in Canada and export our technological expertise around the world."

"The NBHRF is proud of our continued support of industry," said Meaghan Seagrave, NBHRF CEO. "Building strong partnerships like the one with Cloud DX enables us to maximize the impact of our work. We are able to support the best health research for New Brunswick solutions to New Brunswick health challenges."

"It is exciting to see the research being conducted within our health authority," said Barry Strack, Regional Director of Research Services at Horizon Health Network, "Having strong partners in the ecosystem make New Brunswick an attractive place to work and live for physicians and health researchers and provides our patients with opportunities to be involved in clinical studies that may improve their health and well-being."

About the Horizon Health Network

The Horizon Health Network is one of two health authorities in the province of New Brunswick. Cardiovascular Research New Brunswick (CVR-NB) is the clinical research division of the New Brunswick Heart Centre at the Saint John Regional Hospital. The New Brunswick Heart Centre provides cardiac treatment and care for the provinces of New Brunswick and Prince Edward Island.

About the NBHRF

The NBHRF is a not-for-profit organization that co-ordinates, supports and promotes health research in New Brunswick. Their vision is a healthy population, a high performing health system and a vibrant knowledge economy through health research and innovation. NBHRF is governed by a board of 15 directors comprised of key stakeholders from the health research community in New Brunswick.

About Cloud DX

Accelerating virtual healthcare, Cloud DX is on a mission to make healthcare better for everyone. Our Connected Health TM remote patient monitoring platform is used by healthcare enterprises and care teams across North America to manage chronic disease virtually, enable aging in place, and deliver hospital-quality post-surgical care in the home. Our partners achieve better healthcare and patient outcomes, reduce the need for hospitalization or re-admission, and reduce healthcare delivery costs through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist, and one of "Canada's Ten Most Prominent Telehealth Providers." In 2021, Cloud DX became an exclusive partner of Medtronic Canada.

Cloud DX Investor Site https://ir.clouddx.com/overview/default.aspx

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Social Media Links

Cloud DX

Twitter https://twitter.com/CloudDX
Facebook https://www.facebook.com/clouddxinc/
LinkedIn https://www.linkedin.com/company/cloud-dx/
Instagram https://www.instagram.com/cloud.dx/

NBHRF

Twitter https://twitter.com/NBHRF
Facebook https://www.facebook.com/NBHRF
LinkedIn https://www.linkedin.com/company/nbhrf-frsnb

For media inquiries please contact:

Cloud DX NBHRF
Janine Scott Shannon Payne
Marketing Lead Director of Marketing
888-543-0944 506-455-8886
janine.scott@CloudDX.com shannon.payne@nbhrf.com

For investor inquiries please contact:

Jay Bedard
Cloud DX Investor Relations
647-881-8418
jay.bedard@CloudDX.com

SOURCE: Cloud DX Inc.



View source version on accesswire.com:
https://www.accesswire.com/683310/Cloud-DX-Receives-Partnership-Funding-for-Clinical-Research-of-Next-Generation-Wrist-Worn-Vital-Sign-Monitoring-Device

News Provided by ACCESSWIRE via QuoteMedia

CDX:CA
Cloud DX

Cloud DX

Overview

The COVID-19 global pandemic shook traditional healthcare structures on a global scale in 2020. There has been an urgent need for integrated systems to manage the influx of patients and new social distancing measures, which forced many to delay seeking in-person medical attention. In identifying this gap in the healthcare system, digitally driven telemedicine companies are leading the way to innovate and improve healthcare for all in this increasingly digital age.

By 2022, the global healthcare market is forecasted to grow to US$11.9 trillion, with the digital healthcare sector to grow by a projected compound annual growth rate (CAGR) of 38 percent by 2026. In dealing with the aftermath of this pandemic, investing in healthcare and wellness technology is investing in the healthcare systems we’ve needed for a long time.

Keep reading... Show less
Cloud DX: Digital and Virtual Healthcare, CEO Clip Video

Cloud DX: Digital and Virtual Healthcare, CEO Clip Video

Cloud DX Inc. (TSXV: CDX Robert Kaul, CEO & Founder, speaks about the company's game-changing partnership with Medtronic, a global leader in healthcare technology.

Keep reading... Show less
Cloud DX Announces Voluntary Extension of Lock-up Agreements with Company Insiders

Cloud DX Announces Voluntary Extension of Lock-up Agreements with Company Insiders

News in Summary

  • Cloud DX insiders (as defined by the TSX Venture Exchange) holding approximately 33% of the issued and outstanding shares of Cloud DX Inc. voluntarily extend the release date under lock-up agreements
  • This six-month voluntary extension of their resale restrictions indicates that the board and management are confident about the company's growth prospects

Cloud DX Inc. (the "Company" or "Cloud DX") (TSXV:CDX) (OTCQB:CDXFF), announces today that certain company ‘insiders' (as defined by the TSX Venture Exchange) have voluntarily agreed to extend the release dates under the lock-up agreements they entered into in connection with the Company's ‘Qualifying Transaction' which closed on April 15, 2021. Insiders holding approximately 33% of the issued and outstanding shares of the Company have agreed to extend the lock-up to be effective until October 31, 2022

Keep reading... Show less
Cloud DX Inc. Announces Update to Brokered Private Placement

Cloud DX Inc. Announces Update to Brokered Private Placement

Cloud DX Inc. ("Cloud DX" or the "Company") (TSXV:CDX) announces that it has updated the terms of its private placement previously announced on January 4, 2022 of Convertible Debenture Units (the "Updated Offering") with Echelon Wealth Partners Inc. as lead agent and sole book runner (the "Agent"). The Company expects the initial closing of the Updated Offering will be on or about January 25, 2022

In connection with the Updated Offering the Agent will offer for sale up to 3,000 convertible debenture units of the Company (the "Convertible Debenture Units") at a price of $1,000 per Convertible Debenture Unit for aggregate gross proceeds of up to $3,000,000. The Agent has been granted an option to sell up to 450 additional Convertible Debenture Units for maximum aggregate gross proceeds under the Updated Offering of $3,450,000. Pursuant to the Updated Offering, each Convertible Debenture Unit will be comprised of $1,000 principal amount unsecured convertible debenture (each, a "Debenture") and 1,430 common share purchase warrants of the Company (each, a "Warrant"). The Debentures will mature on the date that is 36 months from the date of issuance (the "Maturity Date") and shall bear interest at a simple rate of 10% per annum. Interest will be payable quarterly on the last business day of each quarter, commencing on March 31, 2022. The principal amount of the Debentures, or any portion thereof, may be converted at the election of the holder thereof into common shares in the capital of the Company ("Common Shares") at a conversion price of $0.35 per Common Share (the "Conversion Price") at any time prior to the Maturity Date. Each Warrant will entitle the holder thereof to acquire one Common Share at a price of $0.50 per Common Share for a period of 24 months from the closing date of the Updated Offering.

Keep reading... Show less
Cloud DX Announces Contracts with US Primary Care Clinics

Cloud DX Announces Contracts with US Primary Care Clinics

Cloud DX and partner Maxwell Telecare sign three new clinics for Remote Patient Monitoring (RPM) deployment, expanding on its Maxwell partnership

News in Summary

Keep reading... Show less
Cloud DX Announces Multi-Year Contract with Ontario Clinic

Cloud DX Announces Multi-Year Contract with Ontario Clinic

Cloud DX Announces Multi-Year Contract with Ontario Clinic

Combining Telehealth and Remote Monitoring, Cloud DX's Connected Health™ enables the clinic to deliver virtual physical rehabilitation safely and efficiently in patient homes

Keep reading... Show less
NANALYSIS SCIENTIFIC CORP. ANNOUNCES MARKETED PUBLIC OFFERING OF UP TO C$8 MILLION

NANALYSIS SCIENTIFIC CORP. ANNOUNCES MARKETED PUBLIC OFFERING OF UP TO C$8 MILLION

/NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES /

Nanalysis Scientific Corp. (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1) (" Nanalysis ", or the " Company ") is pleased to announce that it has filed a preliminary short form prospectus with the securities commissions or similar regulatory authorities in each of the provinces of Canada except for the Province of Québec (the " Canadian Jurisdictions "), in connection with a best efforts marketed public offering (the " Offering ") of common shares (the " Common Shares ") of the Company at an offering price of $1.10 per Common Share for gross proceeds of up to approximately $8,000,000 .

Keep reading... Show less
Nanalysis Enters into a Letter of Intent to Acquire Quad Systems AG

Nanalysis Enters into a Letter of Intent to Acquire Quad Systems AG

Nanalysis Scientific Corp. ( TSXV:NSCI , OTCQX:NSCIF, FRA:1N1) ("Nanalysis" or the "Company") is pleased to announce that it has entered into a letter of intent to acquire QUAD Systems AG (Quad Systems), a Zurich -based Nuclear Magnetic Resonance (NMR) company focused on high-field NMR for pharmaceutical and other vertical markets.

Keep reading... Show less
Brandon Tatum to Headline KWESST Non-Lethal Product Launch At 2022 SHOT Show

Brandon Tatum to Headline KWESST Non-Lethal Product Launch At 2022 SHOT Show

Former Tucson Police Officer, Influencer, and Media Star to Unveil Company's 'Para Ops' Personal Defense System in Las Vegas

KWESST Micro Systems Inc. (OTCQB: KWEMF) (TSXV: KWE) ("KWESST," or the "Company"), a leader in providing next-generation tactical systems for security forces and personal defense, is pleased to announce that former Tucson police officer and Company spokesperson Brandon Tatum will headline a major product launch for the Company at the Shooting, Hunting, and Outdoor (SHOT) trade show in Las Vegas, Nevada this month.

Keep reading... Show less
KWESST Announces Branding of Non-Lethal Low Energy Cartridge  System in Conjunction with Launch at SHOT Show 2022 - Booth # 40022

KWESST Announces Branding of Non-Lethal Low Energy Cartridge System in Conjunction with Launch at SHOT Show 2022 - Booth # 40022

KWESST Micro Systems Inc. (TSXV: KWE) (OTCQB: KWEMF) ("KWESST" or the "Company") today announced that it will be launching its non-lethal Low Energy Cartridge (LEC) product line under the brand PARA OPS in conjunction with the opening of the 2022 SHOT Show in Las Vegas January 18-21. The PARA OPS website which can be found at www.para-ops.com and it will go live the on January 17, the day before the SHOT Show. You can visit KWESST at the SHOT Show at booth #40022.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7366/110116_4f007e92e4f9aafd_002full.jpg

Keep reading... Show less
Nanalysis Announces the Closing of Acquisition of K' Technologies Inc.

Nanalysis Announces the Closing of Acquisition of K' Technologies Inc.

Nanalysis Scientific Corp. ( TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1) ("Nanalysis" or the "Company") is pleased to announce that it has successfully closed the previously announced acquisition of K'(Prime) Technologies Inc. (KPrime), a North American sales and service company, with a particular focus on scientific instrumentation for pharma, food, chemical and oil & gas customers, as well as imaging systems for security applications.

Keep reading... Show less
KWESST Announces $400,000 in Police Orders for ARWEN Products

KWESST Announces $400,000 in Police Orders for ARWEN Products

KWESST Micro Systems Inc. (TSXV: KWE) (OTCQB: KWEMF) ("KWESST" or the "Company") is pleased to announce that it has received orders from three law enforcement agencies for approximately $400,000 in ARWEN products (all values in CAD). One order from an overseas national police agency is for approximately $250,000 to be shipped next month. The other two orders are from Canadian law enforcement agencies, with one order shipped in late December 2021 and the other scheduled to ship this month.

"It is gratifying to see this early acceleration in the pace of orders from our recent acquisition of ARWEN," said Jeff MacLeod, Founder, President and CEO of KWESST. "This reinforces our conviction that there is strong growth potential for ARWEN products around the world, particularly in an environment of heightened civil unrest and anxiety about rising crime."

Keep reading... Show less

Latest Press Releases

Related News

×